Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Terminated

• Conditions: Acute Leukemia of Ambiguous Lineage; Acute Myeloid Leukemia
• Interventions: Biological: Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion; Drug: Cytarabine; Drug: Filgrastim; Drug: Fludarabine Phosphate

• Registration Number: NCT01701323
• Lead Sponsor: Nohla Therapeutics, Inc.

Brief Summary

This pilot clinical trial studies infusion of expanded cord blood hematopoietic progenitor cells following combination chemotherapy in treating younger patients with acute myeloid leukemia that has relapsed or has not responded to treatment. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy also kills healthy infection-fighting cells, increasing the risk of infection. The infusion of expanded cord blood hematopoietic progenitor cells may be able to replace blood-forming cells that were destroyed by chemotherapy. This cellular therapy may decrease the risk of infection following chemotherapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-10-03
• Study First Submitted QC: 2012-10-03
• Study First Posted: 2012-10-05
• Study Start: 2012-12-10
• Primary Completion: 2018-05-10
• Study Completion: 2018-05-10
• Status Verified: 2019-02
• Last Update Submitted: 2019-02-27
• Last Update Posted: 2019-03-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

• Patients must have a diagnosis of AML or acute leukemia of ambiguous lineage according to World Health Organization (WHO) classification with >= 5% of disease in bone marrow (BM)

• Recipients of prior allogeneic hematopoietic stem cell transplantation for AML or acute leukemia of ambiguous lineage are eligible if they do not have graft-versus-host disease (GVHD) or they have quiescent GVHD whether or not they are receiving immunosuppressive therapy

• Must have a Lansky or Karnofsky performance status of >= 50; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age

• Patients must have recovered from the acute toxicity of all prior chemotherapy

• The following amounts of time must have elapsed prior to entry on study:

  • 2 weeks from local radiation therapy (XRT)
  • 8 weeks from prior craniospinal or if > 50% of the pelvis has been irradiated
  • 6 weeks must have elapsed if other bone marrow radiation has occurred

• Adequate cardiac, renal, pulmonary, and hepatic function

• Patient must have a life expectancy of at least 2 months

• Females of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment

• Females of childbearing potential and males should agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation

Read More

Exclusion Criteria

• Recipients of prior allogeneic hematopoietic stem cell transplant (HSCT) with active acute or chronic GVHD
• Patients with history of Down's syndrome, Fanconi anemia or other known marrow failure condition
• Patients currently receiving other investigational drugs are not eligible
• Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol with the exception of intrathecal chemotherapy; this includes the tyrosine kinase inhibitor sorafenib which must not be initiated until patient demonstrates count recovery
• Patients with a systemic fungal, bacterial, viral, or other infection not controlled despite appropriate antibiotics or other treatment; uncontrolled systemic infections require infectious disease consultation for verification
• Patients who are platelet refractory prior to initiation of protocol therapy
• Pregnant or lactating patients
• Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (Ex-vivo expanded cord blood progenitors)	Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion	Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex-vivo expanded cord blood progenitor cells IV over 30 minutes on day 8.
Treatment (Ex-vivo expanded cord blood progenitors)	Cytarabine	Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex-vivo expanded cord blood progenitor cells IV over 30 minutes on day 8.
Treatment (Ex-vivo expanded cord blood progenitors)	Filgrastim	Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex-vivo expanded cord blood progenitor cells IV over 30 minutes on day 8.
Treatment (Ex-vivo expanded cord blood progenitors)	Fludarabine Phosphate	Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex-vivo expanded cord blood progenitor cells IV over 30 minutes on day 8.

Primary Outcome Measures

Name	Time	Method
Incidence of NCI CTCAE grade > 3 infusional toxicities	Up to 2 years
Incidence of platelet refractoriness in the presence of alloimmunization as a direct result of ex vivo expanded cord blood product infusion	Up to 2 years
Incidence of delayed marrow recovery	Up to day 42	Failure to achieve ANC \>= 500 cells/µl by day 42 post treatment with marrow cellularity \< 5% and marrow blast count \< 5%.
Occurrence of transfusion associated graft versus host disease	Up to 2 years
Rate of treatment related mortality	Up to 2 years

Secondary Outcome Measures

Name	Time	Method
Rate of complete remission	Up to 2 years
Incidence of NCI CTCAE grade > 3 chemotherapy-related toxicity in the first 30 days following fludarabine phosphate, cytarabine, and filgrastim (FLAG) therapy	First 30 days following FLAG administration
Incidence of NCI CTCAE grade 3 or 4 infections	First 30 days following FLAG administration
Overall survival	Up to 2 years
Leukemia-free survival	Up to 2 years
Time to neutrophil recovery	Up to 2 years	ANC \>= 100 cells/ul and 500 cells/ul
In vivo persistence of ex vivo expanded cellular therapy	Up to 2 years	Assessed by peripheral blood cell sorted deoxyribonucleic acid (DNA) chimerisms of the cluster of differentiation myeloid and lymphoid cell lineages as well as whole marrow chimerisms.
Patient and infused expanded cord blood cells immune interaction	Up to 2 years	Assessed by performing host-donor studies.

Trial Locations

Locations (2)

Emory University/Winship Cancer Institute; 🇺🇸 Atlanta, Georgia, United States

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; 🇺🇸 Seattle, Washington, United States